hit counter
Aerie Pharmaceuticals, Inc. (AERI) Stock News Sentiment & Price - Sentifly
AERI - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Aerie Pharmaceuticals, Inc. (AERI)

USA
Drug Manufacturers - Major
NASDAQ
AERI Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
AERI Latest news
Business Wire
Neutral
Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences
2021-11-09 16:30

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Benjamin McGraw, III, Pharm.D., Interim Executive Chairman, will participate in the following virtual investor conferences. Stifel 2021 Virtual Healthcare Conference Date: T

Seeking Alpha
Neutral
Aerie Pharmaceuticals' (AERI) Management on Q3 2021 Results - Earnings Call Transcript
2021-11-07 05:30

Aerie Pharmaceuticals' (AERI) Management on Q3 2021 Results - Earnings Call Transcript

Zacks Investment Research
Neutral
Aerie's (AERI) Q3 Earnings Miss Estimates, Revenues Rise Y/Y
2021-11-05 12:13

Aerie (AERI) incurs wider-than-expected loss in the third quarter of 2021 while sales match expectations.

Zacks Investment Research
Positive
Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates
2021-11-04 18:19

Aerie (AERI) delivered earnings and revenue surprises of -16.13% and 0.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Business Wire
Neutral
Aerie Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
2021-11-04 16:01

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today reported financial results for the third quarter ended September 30, 2021 and provided a general business update. “Our third quarter 2021 results reflect nearly 46 percent growth in net revenues and 26 percent growth in bottle volumes for our U.S. glaucoma franchise compared to the third quarter of 2020. Our net revenue per bottle remained stable at $89 in the third quarter of 2

Zacks Investment Research
Negative
Aerie Pharmaceuticals (AERI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
2021-10-28 16:48

Aerie (AERI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire
Neutral
Aerie Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call on Thursday, November 4, 2021
2021-10-28 07:30

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, announced today that its third quarter 2021 financial results will be released after the market closes on Thursday, November 4, 2021. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company's financial results and provide a general business update. The live webcast and a replay may be accessed by visiting the Co

Business Wire
Neutral
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Glaucoma Innovation Showcase
2021-10-21 16:01

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that Tom Mitro, President and Chief Operating Officer presented an overview on Aerie's glaucoma franchise at the Ophthalmology Innovation Summit Glaucoma Innovation Showcase. The slide presentation provides an update on Aerie's franchise growth in the United States, as well as progress toward market entry in Europe and Japan. The slide presentation from today's event

Business Wire
Neutral
Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan
2021-10-12 06:30

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today reported positive topline results for the Company's Phase 3 clinical trial in Japan evaluating netarsudil ophthalmic solution 0.02% (“netarsudil 0.02%”) versus ripasudil hydrochloride hydrate ophthalmic solution 0.4% (“ripasudil 0.4%”). The results showed that netarsudil 0.02% once daily was superior to ripasudil 0.4% twice daily in lowering intraocular pressure (“IOP”) at week

Business Wire
Neutral
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Retina Innovation Showcase
2021-10-07 16:01

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that Casey Kopczynski, Ph.D., Chief Scientific Officer presented an overview on Aerie's retina product candidates, at the Ophthalmology Innovation Summit Retina Innovation Showcase. The slide presentation addresses Aerie's proprietary PRINT® drug delivery platform and retina product candidates AR-1105 (dexamethasone implant, Phase 3 ready), AR-13503 (Rho kinase/Protei

Loading more news...